*

AllCells Announces First to Market Launch of In Stock GMP-Compliant Cryopreserved Leukopaks

AllCells Announces First to Market Launch of In Stock GMP-Compliant Cryopreserved Leukopaks

Debbie King, Scientific Writer

Collected from qualified healthy donors that meet baseline FDA 21 CFR 1271 requirements, industry’s first In Stock GMP-compliant Cryopreserved Leukopaks significantly decrease lead time

GMP-Compliant Cryopreserved Leukopaks In Stock Ready to Ship

AllCells, the industry leader in the procurement and customization of human-derived hematological tissues and services, is pleased to announce the launch of its In Stock GMP-Compliant Cryopreserved Leukopaks. While donor customizations are often required for immunotherapy programs, many operations in late-stage clinical phases are supported by GMP-compliant Leukopaks collected from qualified healthy donors that meet baseline FDA 21 CFR 1271 requirements. Reducing clinical grade product lead time affords researchers a higher degree of flexibility and improved access to high-quality starting material to readily respond to changes and meet condensed timelines. This industry first off-the-shelf offering is one of many new GMP-compliant solutions that AllCells is providing to meet the growing and rapidly evolving needs of the cell and gene therapy market.

GMP-compliant Leukopak collections from validated donors occur at AllCells-Leukolab centers and are immediately transferred to adjacent FDA-approved processing facilities for cryopreservation using industry best practices and state-of-the-art equipment in cleanroom environments. The GMP processing facility is operated by a dedicated team under a robust quality framework and operational oversight that, along with an environmental monitoring program, ensures stringent control and compliance of the aseptic conditions during manufacturing operations to safeguard product quality, consistency and integrity.

“The continued advancement and diversification of our clinical grade portfolio is a top mandate at AllCells for 2022 and beyond,” said Danny Zheng, CEO. “This new In Stock GMP-compliant Leukopak offering sets AllCells apart in the industry and gives customers access to off-the-shelf, ready-to-ship clinical grade material with shortened lead times – keeping pace with rapid innovations in this age of genomic medicine.”

Donor Management Services

A Donor-Centric Approach to Cell and Gene Therapy

February 3, 2022


AllCells cryopreserved cells in vial

FAQ Series: The Science Behind Cryopreservation

January 11, 2022


Subscribe to Our Blog

Stay current with the AllCells Blog. Get email updates with helpful resources for biomedical researchers:

Customer Service

How Can We Help You?


Looking for research tips? Need help sourcing materials? How about a few more articles on therapies or processes? At AllCells, we believe that partnerships create the best pathways to success. Our Customer Success Team has years of industry experience and a wealth of resources to help you get the most out of your cellular products. We’re only a few clicks away.

Contact Us
Have a question? Let’s chat.